Evaluation of the Care Pathway in the Context of the Dispensing of Emicizumab (Hemlibra) in Community Pharmacies in France: Protocol for a Cross-sectional Study Based on the Kirkpatrick Model

BACKGROUND: Commercialized since 2019, emicizumab (Hemlibra) was available only in French hospital pharmacies for prophylaxis of hemophilia A with or without inhibitors. Since June 15, 2021, patients can choose between a hospital and community pharmacy. These changes in the care pathway have importa...

Descripción completa

Detalles Bibliográficos
Autores principales: Fraticelli, Laurie, Freyssenge, Julie, Promé-Combel, Emilie, Agnellet, Eléonore, Dargaud, Yesim, Chamouard, Valérie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JMIR Publications 2023
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10034610/
https://www.ncbi.nlm.nih.gov/pubmed/36884286
http://dx.doi.org/10.2196/43091

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10034610/
https://www.ncbi.nlm.nih.gov/pubmed/36884286
http://dx.doi.org/10.2196/43091

Ejemplares similares